Do Kim
Stock Analyst at Piper Sandler
(1.97)
# 2,858
Out of 4,760 analysts
98
Total ratings
44%
Success rate
0.54%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $33.03 | +90.74% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $18.13 | +153.79% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $488.34 | -39.39% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $114.43 | -2.12% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $21.66 | +301.66% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.76 | +733.33% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $0.91 | +6,515.21% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $19.49 | +2.62% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $11.44 | +275.87% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $36.93 | -13.35% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $2.23 | +886.55% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $34.50 | -44.93% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.29 | +598.69% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $238.74 | -22.51% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $10.65 | +8,350.70% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $61.45 | -43.04% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $0.96 | +1,983.55% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $33.03
Upside: +90.74%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $18.13
Upside: +153.79%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $488.34
Upside: -39.39%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $114.43
Upside: -2.12%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $21.66
Upside: +301.66%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.76
Upside: +733.33%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $0.91
Upside: +6,515.21%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $19.49
Upside: +2.62%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $11.44
Upside: +275.87%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $36.93
Upside: -13.35%
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $2.23
Upside: +886.55%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $34.50
Upside: -44.93%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.29
Upside: +598.69%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $238.74
Upside: -22.51%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $10.65
Upside: +8,350.70%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $61.45
Upside: -43.04%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $0.96
Upside: +1,983.55%